Register Login

Alector Inc (ALEC)

  • Event
  • Aug. 04, 2022, 20:33 UTC

(75% Positive) Alector, Inc. (ALEC) Announces Enrollment Update for submitted Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 7:04 p.m.

    📋 Alector, Inc. (ALEC) - Clinical Trial Update

    Filing Date: 2022-08-04

    Accepted: 2022-08-04 16:33:28

    Event Type: Clinical Trial Update

    Event Details:

    Alector Inc (ALEC) Announces Clinical Trial Update Alector Inc (ALEC) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: submitted, continues
    • Diseases/Conditions: developing new ap
    • Clinical Stage: pivotal study, Phase 2 study
      • targeting myeloid biology, this brings us closer to achieving our goal of building a portfolio of innate immuno-oncology therapies by utilizing the company’s expertise in the central and peripheral innate immune system.” “Alongside these encouraging clinical updates, Alector continues to attract world class talent and we are delighted to announce that Peter Heutink, Ph.D., will be joining us as Chief Scientific Officer. Peter brings considerable experience in human genetics of neurodegenerative diseases, functional genomics, and induced pluripotent stem cell (iPSC) technology that will help drive science and discovery at Alector.” Clinical Programs Immuno-Neurology Portfolio Progranulin Assets (Latozinemab, AL101) •Alector continues to progress the INFRONT-3 randomized, placebo-controlled, pivotal Phase 3 trial evaluating the efficacy and safety of latozinemab in at-risk and symptomatic patients with FTD-GRN. The company continues to build awareness of FTD, support genetic testing and educate the FTD patient community about the INFRONT-3 pivotal study to support clinical trial enrollment. •The company expects to report data at a medical conference later this year from the Phase 1 trial of AL101 in healthy volunteers. AL101 is being developed to elevate progranulin levels in a manner similar to latozinemab (AL001) with plans to investigate AL101 for the treatment of AD and Parkinson’s disease. TREM2 and SIGLEC 3 Assets (AL002, AL003) •Enrollment in the INVOKE-2 Phase 2 study of AL002 continues with no additional serious adverse events related to ARIA following the exclusion of APOE e4/e4 homozygous patients. The company is implementing MRI monitoring prior to dose escalation for all clinical trial participants, consistent with recently published guidelines for ARIA monitoring and management. The INVOKE-2 Phase 2 clinical trial is designed to evaluate the efficacy and safety of AL002 in slowing disease progression in individuals with early AD. AL002 is being developed in collaboration with AbbVie and targets Triggering Receptor Expressed on Myeloid Alector Reports Second Quarter 2022
      • targeting an Alzheimer’s disease risk gene Expanding clinical sites to drive additional enrollment in the INFRONT-3 pivotal study for latozinemab (AL001) and enrollment continues in the INVOKE-2 Phase 2 study for AL002 Peter Heutink, Ph.D., to join company as Chief Scientific Officer John Maraganore appointed as strategic advisor $808.9 million in cash, cash equivalents and investments provide runway into H2-2024

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Alector Inc
    • CIK: 0001653087
    • Ticker Symbol: ALEC
    • Period End Date: 2022-08-04
    • Document Type: 8-K

Search

News categories